Leucine-Rich Repeat Kinase 2 inhibitor LRRK2-IN-1 (1mg)

Leucine-Rich Repeat Kinase 2 (LRRK2) is a member of the leucine-rich repeat kinase family. Mutations in the LRRK2 gene have been linked with late-onset autosomal dominant Parkinsona€s disease (PD). A recent screening identified the analog LRRK2-IN-1 as a potent and selective inhibitor of LRRK2. This research by Deng et al (2011, Nat Chem Biol) showed that LRRK2-IN-1 suppressed LRRK2 kinase activity in vivo leading to dephosphorylation of Ser910/Ser935, loss of 14-3-3 binding and accumulation of LRRK2 within aggregrate fibrillar structures. LRRK2-IN-1, is the first selective and potent inhibitor of LRRK2. LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13nM and 6nM respectively (Deng et al 2011, Nat Chem Biol).

Store dry, unopened vial protected from light for up to 3 months at RT or at -70AC for up to 1 year. Reconstitute product in 100% ACS grade DMSO and store at -80AC, in aliquots, protected from light, for up to 1 month. Prevent multiple freeze-thaw cycles. CAS Number 1234480-84-2.

1. Deng X. et al (2011) Characterization of a selective inhibitor of the Parkinson's disease kinase LRRK2 Nat Chem Biol. 2011 Apr, 7(4):203-5.